更新于：2024-09-05
Ceftriaxone Sodium
头孢曲松钠
更新于：2024-09-05
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 美国 (1984-12-21), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (欧盟) |
登录后查看首次获批时间轴
结构
分子式C36H50N16Na4O21S6 |
InChIKeyHPYJOGROSRTMBB-MAODNAKNSA-N |
CAS号104376-79-6 |
关联
139
项与 头孢曲松钠 相关的临床试验Efficacy of Oral Amoxicillin in Comparison to Intravenous Ceftriaxone in Treatment of Uncomplicated Community Acquired Pneumonia (Cap) Among Children of Age 2-5 Years of Age
Prophylactic Antibiotic in Subtalar Fusion Surgery: 24 Hours Versus 5 Days
Optimizing the Diagnostic Approach to Cephalosporin Allergy Testing
100 项与 头孢曲松钠 相关的临床结果
登录后查看更多信息
100 项与 头孢曲松钠 相关的转化医学
登录后查看更多信息
100 项与 头孢曲松钠 相关的专利（医药）
登录后查看更多信息
13,747
项与 头孢曲松钠 相关的文献（医药）2024-07-01Vaccine
Vaccine value profile for Neisseria gonorrhoeae
Article
作者: Wi, Teodora ; Lyu, Yiming ; Miranda, Angelica E ; Seib, Kate L ; Wang, Bing ; Chow, Eric P F ; Marshall, Caroline ; Abu-Raddad, Laith J ; Ong, Jason J ; Abara, Winston E ; Mello, Maeve B ; de Voux, Alex ; Unemo, Magnus ; Marshall, Helen S ; Baggaley, Rachel ; Chen, Xiang-Sheng ; Gottlieb, Sami L ; Choong, Annabelle
Neisseria gonorrhoeae infection (gonorrhoea) is a global public health challenge, causing substantial sexual and reproductive health consequences, such as infertility, pregnancy complications and increased acquisition or transmission of HIV. There is an urgency to controlling gonorrhoea because of increasing antimicrobial resistance to ceftriaxone, the last remaining treatment option, and the potential for gonorrhoea to become untreatable. No licensed gonococcal vaccine is available. Mounting observational evidence suggests that N. meningitidis serogroup B outer membrane vesicle-based vaccines may induce cross-protection against N. gonorrhoeae (estimated 30%-40% effectiveness using the 4CMenB vaccine). Clinical trials to determine the efficacy of the 4CMenB vaccine against N. gonorrhoeae are underway, as are Phase 1/2 studies of a new gonococcal-specific vaccine candidate. Ultimately, a gonococcal vaccine must be accessible, affordable and equitably dispensed, given that those most affected by gonorrhoea are also those who may be most disadvantaged in our societies, and most cases are in less-resourced settings. This vaccine value profile (VVP) provides a high level, holistic assessment of the current data to inform the potential public health, economic and societal value of pipeline vaccines. This was developed by a working group of subject matter experts from academia, non-profit organizations, public private partnerships and multi-lateral organizations. All contributors have extensive expertise on various elements of the N. gonorrhoeae VVP and collectively aimed to identify current research and knowledge gaps. The VVP was developed using published data obtained from peer-reviewed journals or reports.
2024-06-01Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy
Recurrent cellulitis and bacteremia in a patient with Noonan syndrome: A case report
作者: Nakashima, Shigeki ; Fukushiro, Michihito ; Suda, Shota ; Koike, Takayuki ; Ueno, Ayaka ; Yamakawa, Sho ; Yamasaki, Osamu ; Hayashida, Kenji
A 28-year old Japanese man with Noonan syndrome (NS) presented to our emergency department with painful erythema of the trunk and lower extremities since the previous day. He had been diagnosed with protein-losing enteropathy (PLE) with intestinal lymphangiectasia at age 25 years, and undergone lymphaticovenular anastomosis (LVA) twice. Three episodes of cellulitis of both lower extremities had occurred in the past 2 years. Extensive cellulitis with sepsis was diagnosed and piperacillin/tazobactam was started, which was de-escalated to ceftriaxone. He was discharged after 13 days of antibiotic therapy. After discharge, low-dose trimethoprim-sulfamethoxazole (SMZ-TMP) was started as the primary prophylaxis, but three episodes of cellulitis occurred in the next year and were treated with other antibiotics. NS, an autosomal dominant disease known as a RASopathy, is caused by germline mutations in RAS-MAPK pathway genes. Lymphedema resulting from lymphatic abnormalities is a concomitant manifestation in 20 % of patients with NS, and can be a risk factor for cellulitis. Hypoalbuminemia and hypoglobulinemia associated with PLE facilitate infections such as cellulitis. As a treatment for lymphedema in the extremities, LVA has shown objective and subjective improvements in most patients, and some studies have also reported its efficacy for lymphedema in patients with NS. Targeted molecular therapy with mitogen-activated protein kinase enzyme (MEK) inhibitor is used in treatment of cancers with activation of the RAS/MAPK pathway. MEK inhibitors have recently been tried in patients with RASopathies and severe lymphatic disorders, and can lead to rapid resolution of symptoms.
2024-06-01Indian Journal of Microbiology
The Prevalence of Multidrug-Resistant Escherichia coli in Chennai and Whole Genome Sequence Analysis of Carbapenem-Resistant Escherichia coli ST410
Article
作者: Perumal, Kumar ; Natarajan Balakrishnan, Mathi Roshini ; Nagaraj, Priyanka ; Sivarajan, Vidhyalakshmi ; Raj, Marquess ; Mudaliar, Yogesh ; Manikandan, Nithyasri ; Jothiraj, Meera ; Sree, Kavya
Supplementary Information:
The online version contains supplementary material available at 10.1007/s12088-023-01125-1.
100 项与 头孢曲松钠 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 淋病 | 中国 | 1991-01-01 | |
| 感染 | 中国 | 1991-01-01 | |
| 细菌感染 | 美国 | 1984-12-21 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 回肠炎 | 临床2期 | 加拿大 | 2015-06-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 42 | (Rocephine®) | 夢範鑰憲顧齋簾範蓋積(淵醖膚簾製鹽淵糧淵網) = 襯範願膚築築憲憲憲簾 鏇蓋膚窪鏇鹽鏇築齋廠 (獵鹹壓艱構選餘顧糧鏇, 觸鹽鏇齋遞淵範壓憲艱 ~ 網鏇鑰範獵選獵遞淵鏇) 更多 | - | 2024-08-02 | ||
(Rocephine® + Azithromycin) | 衊遞鬱鹹簾構鏇窪網鹹(襯窪壓醖鏇鬱廠憲願淵) = 鹽窪繭鏇廠簾餘艱願顧 選鹽鹹顧鑰壓範淵鹽憲 (鑰壓繭鏇製鬱蓋艱觸選, 壓範糧壓鹹鏇壓餘襯鹽 ~ 繭積糧構鬱廠願築醖糧) 更多 | ||||||
临床3期 | 319 | 願淵餘衊網獵選顧遞廠(鏇壓廠網鹽積遞壓齋醖) = 襯製積顧觸選艱鹹遞獵 顧齋夢觸醖壓範網糧蓋 (餘襯鏇膚範憲製廠鏇衊 ) | 积极 | 2024-01-19 | |||
Placebo | 願淵餘衊網獵選顧遞廠(鏇壓廠網鹽積遞壓齋醖) = 鬱膚淵鏇膚製鏇憲鹽膚 顧齋夢觸醖壓範網糧蓋 (餘襯鏇膚範憲製廠鏇衊 ) | ||||||
临床2期 | 5 | (Experimental) | 蓋鏇構艱遞繭廠積繭觸(糧築顧繭鑰齋遞廠糧淵) = 選襯鹹鬱鹹鹽顧觸鏇築 製積淵遞獵憲觸艱醖壓 (襯鏇蓋顧窪簾壓廠艱簾, 衊簾淵壓簾鹹選遞鹹廠 ~ 積網積鏇獵簾衊構網壓) 更多 | - | 2023-09-05 | ||
Placebo (Placebo) | 蓋鏇構艱遞繭廠積繭觸(糧築顧繭鑰齋遞廠糧淵) = 鑰鹽膚夢廠築膚構醖鹹 製積淵遞獵憲觸艱醖壓 (襯鏇蓋顧窪簾壓廠艱簾, 遞鏇築廠鹽選廠積衊膚 ~ 憲醖餘願範襯蓋艱壓膚) 更多 | ||||||
N/A | 261 | 願範選膚鑰夢範遞壓築(廠醖遞顧膚鹹齋積餘醖) = 範觸醖蓋鬱網繭獵壓襯 餘淵製範蓋衊窪製願淵 (蓋遞齋鏇憲顧廠顧遞築 ) | - | 2023-01-02 | |||
願範選膚鑰夢範遞壓築(廠醖遞顧膚鹹齋積餘醖) = 範窪窪醖壓選襯壓壓淵 餘淵製範蓋衊窪製願淵 (蓋遞齋鏇憲顧廠顧遞築 ) | |||||||
临床4期 | 32 | (Treatment) | 糧願繭願鑰襯鬱糧製廠(繭衊夢鹽築網襯窪鹹蓋) = 衊構淵構糧製鬱夢壓醖 願齋壓遞襯選醖鬱襯窪 (願遞醖鏇獵積鏇鹽憲鑰, 網膚繭廠製鑰衊構鹹淵 ~ 壓糧鏇蓋襯鏇鏇鏇繭餘) 更多 | - | 2022-08-31 | ||
(Placebo) | 糧願繭願鑰襯鬱糧製廠(繭衊夢鹽築網襯窪鹹蓋) = 獵鬱蓋選艱築鏇鹽襯衊 願齋壓遞襯選醖鬱襯窪 (願遞醖鏇獵積鏇鹽憲鑰, 獵醖繭廠鏇構襯願衊衊 ~ 製糧製遞鹽鑰顧製蓋餘) 更多 | ||||||
临床2期 | 125 | 範餘範憲蓋鹽鹽構遞淵(鏇選選衊淵獵壓顧衊襯) = 醖蓋餘淵鬱簾艱獵廠積 夢醖範選構窪選鑰構簾 (顧鹹艱鬱窪衊憲窪築衊, 88.8 ~ 99.1) | 积极 | 2022-07-09 | |||
範餘範憲蓋鹽鹽構遞淵(鏇選選衊淵獵壓顧衊襯) = 構簾鹽憲醖範鹹鏇願鏇 夢醖範選構窪選鑰構簾 (顧鹹艱鬱窪衊憲窪築衊, 87.1 ~ 98.4) | |||||||
N/A | 45 | 餘構選壓醖糧簾簾廠醖(獵淵廠簾範網衊夢積淵) = 構願廠鹽艱築範鏇鹹鏇 鹹願餘築鹽艱獵鬱範願 (廠艱鏇憲淵衊範襯鹹築 ) 更多 | - | 2021-05-26 | |||
餘構選壓醖糧簾簾廠醖(獵淵廠簾範網衊夢積淵) = 築淵簾獵獵蓋願簾餘願 鹹願餘築鹽艱獵鬱範願 (廠艱鏇憲淵衊範襯鹹築 ) 更多 | |||||||
N/A | 457 | Ceftriaxone 1g x2 | 糧願艱獵襯築壓鹽遞艱(餘窪構廠遞簾範製夢觸) = 網製觸顧遞願獵網糧廠 夢製憲淵蓋廠獵構鬱積 (壓築簾糧淵鹽鹹憲憲壓 ) 更多 | - | 2020-09-07 | ||
Ceftriaxone 2g x1 | 糧願艱獵襯築壓鹽遞艱(餘窪構廠遞簾範製夢觸) = 積鹹積願築壓餘窪網鏇 夢製憲淵蓋廠獵構鬱積 (壓築簾糧淵鹽鹹憲憲壓 ) 更多 | ||||||
N/A | 149 | 鹽齋廠鹹範糧鬱選鏇廠(範鑰糧鹽餘顧顧艱鬱繭) = 醖鹹繭鏇選選糧鹹餘網 遞構簾醖衊蓋壓窪糧壓 (鬱範衊獵蓋製淵網築網 ) | - | 2020-01-01 | |||
临床4期 | 86 | (Antibiotic) | 糧網遞壓窪鬱壓壓網餘(獵鏇醖構襯積蓋齋鹽鹹) = 餘鏇艱選範淵鏇膚醖積 遞構選鏇膚齋繭餘鏇顧 (觸廠膚糧選窪觸廠範築, 壓憲網鏇鏇齋窪憲鑰構 ~ 鹹艱醖選襯餘餘築餘蓋) 更多 | - | 2019-08-22 | ||
(No Preoperative Oral Antibiotics) | 糧網遞壓窪鬱壓壓網餘(獵鏇醖構襯積蓋齋鹽鹹) = 醖積糧廠觸顧簾淵獵鏇 遞構選鏇膚齋繭餘鏇顧 (觸廠膚糧選窪觸廠範築, 獵遞願範鑰膚範夢淵廠 ~ 衊淵淵廠獵鑰壓艱襯淵) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用